Notwithstanding encouraging clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing significant opposition from managed care entities. Such organizations are often building obstacles to access, such as significant cost restrictions and PA that restrict consumer opportunity. Analy